Differential expression of C-Reactive protein and Serum amyloid A in different cell types in the lung tissue of chronic obstructive pulmonary disease patients

BMC Pulmonary Medicine

José Luis López-Campos²  Nicolás Moreno-Mata³  Verónica Sánchez-López¹  Jose Luis Lopez-Villalobos³  Elena Arellano¹  Carmen Calero² 

[1] Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain;CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain;Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Virgen del Rocío, Sevilla, Spain

关键词: Serum amyloid A;    C-reactive protein;    Acute-phase reactants;    Chronic systemic inflammatory syndrome;    Chronic obstructive pulmonary disease;   

Others  :  862832
DOI  :  10.1186/1471-2466-14-95

 received in 2014-02-11, accepted in 2014-05-21,  发布年份 2014

【 摘 要 】

Background

Chronic systemic inflammatory syndrome has been implicated in the pathobiology of extrapulmonary manifestations of chronic obstructive pulmonary disease (COPD). We aimed to investigate which cell types within lung tissue are responsible for expressing major acute-phase reactants in COPD patients and disease-free (“resistant”) smokers.

Methods

An observational case–control study was performed to investigate three different cell types in surgical lung samples of COPD patients and resistant smokers via expression of the C-reactive protein (CRP) and serum amyloid A (SAA1, SAA2 and SAA4) genes. Epithelial cells, macrophages and fibroblasts from the lung parenchyma were separated by magnetic microbeads (CD326, CD14 and anti-fibroblast), and gene expression was evaluated by RT-PCR.

Results

The sample consisted of 74 subjects, including 40 COPD patients and 34 smokers without disease. All three cell types were capable of synthesizing these biomarkers to some extent. In fibroblasts, gene expression analysis of the studied biomarkers demonstrated increased SAA2 and decreased SAA1 in patients with COPD. In epithelial cells, there was a marked increase in CRP, which was not observed in fibroblasts or macrophages. In macrophages, however, gene expression of these markers was decreased in COPD patients compared to controls.

Conclusions

These results provide novel information regarding the gene expression of CRP and SAA in different cell types in the lung parenchyma. This study revealed differences in the expression of these markers according to cell type and disease status and contributes to the identification of cell types that are responsible for the secretion of these molecules.

【 授权许可】

   
2014 Calero et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]López Varela MV, Montes de Oca M, Halbert R, Muiño A, Tálamo C, Pérez-Padilla R, Jardim JR, Valdivia G, Pertuzé J, Menezes AM, PLATINO team: Comorbidities and health status in individuals with and without COPD in five latin american cities: the PLATINO study. Arch Bronconeumol 2013, 49:468-474.
• [2]Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op ’t Roodt J, Wouters EF, Franssen FM: Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:728-735.
• [3]Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W: Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013, 107:1376-1384.
• [4]Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome? Lancet 2007, 370:797-799.
• [5]Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J, EPI-SCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63. BioMed Central Full Text
• [6]Agusti A, Soriano JB: COPD as a systemic disease. COPD 2008, 5:133-138.
• [7]Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
• [8]Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH: Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 2007, 4:626-634.
• [9]Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW: Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011, 37:516-522.
• [10]Sunyer J, Pistelli R, Plana E, Andreani M, Baldari F, Kolz M, Koenig W, Pekkanen J, Peters A, Forastiere F: Systemic inflammation, genetic susceptibility and lung function. Eur Respir J 2008, 32:92-97.
• [11]Sode BF, Dahl M, Nordestgaard BG: Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011, 32:2365-2375.
• [12]Sinden NJ, Stockley RA: Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010, 65:930-936.
• [13]Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, MacCallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005, 128:1995-2004.
• [14]López-Campos JL, Calero C, Rojano B, López-Porras M, Sáenz-Coronilla J, Blanco AI, Sánchez-López V, Tobar D, Montes-Worboys A, Arellano E: C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstructive pulmonary disease patients: a case–control study. Int J Med Sci 2013, 10:938-947.
• [15]Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
• [16]León-Atance P, Moreno-Mata N, González-Aragoneses F, Cañizares-Carretero MÁ, García-Jiménez MD, Genovés-Crespo M, Honguero-Martínez AF, Rombolá CA, Simón-Adiego CM, Peñalver-Pascual R: Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. Arch Bronconeumol 2011, 47:441-446.
• [17]Malle E, De Beer FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427-435.
• [18]Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
• [19]de Andrade M, Li Y, Marks RS, Deschamps C, Scanlon PD, Olswold CL, Jiang R, Swensen SJ, Sun Z, Cunningham JM, Wampfler JA, Limper AH, Midthun DE, Yang P: Genetic variants associated with the risk of chronic obstructive pulmonary disease with and without lung cancer. Cancer Prev Res (Phila) 2012, 5:365-373.
• [20]Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
• [21]Gorska K, Maskey-Warzechowska M, Krenke R: Airway inflammation in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2010, 16:89-96.
• [22]Rahman I, Adcock IM: Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006, 28:219-242.
• [23]Elkington PT, Friedland JS: Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61:259-266.
• [24]Henson PM, Cosgrove GP, Vandivier RW: State of the art. Apoptosis and cell homeostasis in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:512-516.
• [25]Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM: Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993, 147:301-306.
• [26]Auerbach O, Stout AP, Hammond EC, Garfinkel L: Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961, 265:253-267.
• [27]Górska K, Krenke R, Kosciuch J, Korczynski P, Zukowska M, Domagala-Kulawik J, Maskey-Warzechowska M, Chazan R: Relationship between airway inflammation and remodeling in patients with asthma and chronic obstructive pulmonary disease. Eur J Med Res 2009, 14(Suppl 4):90-96.
• [28]Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res 2011, 12:130. BioMed Central Full Text
• [29]Wang Q, Wang Y, Zhang Y, Zhang Y, Xiao W: The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res 2013, 14:67. BioMed Central Full Text
• [30]Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH: Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology 2010, 15:930-938.
• [31]Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
• [32]Togo S, Holz O, Liu X, Sugiura H, Kamio K, Wang X, Kawasaki S, Ahn Y, Fredriksson K, Skold CM, Mueller KC, Branscheid D, Welker L, Watz H, Magnussen H, Rennard SI: Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med 2008, 178:248-260.
• [33]Spurzem JR, Rennard SI: Pathogenesis of COPD. Semin Respir Crit Care Med 2005, 26:142-153.
• [34]Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG: Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:982-988.
• [35]Gaki E, Kontogianni K, Papaioannou AI, Bakakos P, Gourgoulianis KI, Kostikas K, Alchanatis M, Papiris S, Loukides S: Associations between BODE index and systemic inflammatory biomarkers in COPD. COPD 2011, 8:408-413.
• [36]Hillas G, Loukides S, Kostikas K, Bakakos P: Biomarkers obtained by non-invasive methods in patients with COPD: where do we stand, what do we expect? Curr Med Chem 2009, 16:2824-2838.
• [37]Vernooy JH, Küçükaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF: Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166:1218-1224.
• [38]Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
• [39]Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19:1720-1730.